When was Greatbay-bio founded?

Greatbay-bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Greatbay-bio located?

Greatbay-bio is headquartered in Hong Kong, China. It is registered at THIRD FLOOR CONNEXIONS BUILDING 159,PRINCES STREET,IPSWICH,SUFFOLK,IP1 1QJ.

How many employees does Greatbay-bio have?

As of Aug 31, 2026, the latest employee count at Greatbay-bio is 34.

Is Greatbay-bio a funded company?

Greatbay-bio is a funded company, having raised a total of $21.3M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 14, 2020.

When was the latest funding round of Greatbay-bio?

Greatbay-bio's latest funding was a $***** Series B round on Dec 17, 2024, with participation from 2 investors.

Where does Greatbay-bio rank among its competitors?

Greatbay-bio ranks 174th amongst 2025 active competitors, of which 448 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was One Biosciences, which secured $3.76M in Sep, 2026.

Who are the top competitors of Greatbay-bio?

Greatbay-bio's top competitors include Antheia, Transcenta and Akeso. Among them, One Biosciences secured the most recent funding round in September, 2026.

Greatbay-bio - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of AI-based cell line development platform. The company has AlfaMedX a cell culture media development platform for different cell lines and Klone4.0 is a cell line development platform used for cell therapy, molecular diagnosis, and clinical diagnosis.

Website: www.greatbay-bio.com/
Social
Email ID: *****@greatbay-bio.com
Phone Number: +852 **********
Registered Address: THIRD FLOOR CONNEXIONS BUILDING 159,PRINCES STREET,IPSWICH,SUFFOLK,IP1 1QJ

Key Metrics

Founded Year

2019

Location

Hong Kong, China

Stage

Series B

Total Funding

$21.3M in 5 rounds

Latest Funding Round

Series B, Dec 17, 2024, $*****

Investors

Alibaba Entrepreneurs Fund & 15 more

Ranked

174^th among 2025 active competitors

Employee Count

34 as on Aug 31, 2026

Similar Companies

OpenEvidence & 5560 more

View Greatbay-bio's full profile

Greatbay-bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BIO GROUP LIMITED CIN: 6019372 , United Kingdom, Active	Dec 04, 2006	-	-

Greatbay-bio has raised a total funding of $21.3M over 5 rounds. Its first funding round was on Jan 14, 2020. Its latest funding round was a Series B round on Dec 17, 2024 for $*****. 2 investors participated in its latest round. Greatbay-bio has 16 institutional investors.

Here is the list of recent funding rounds of Greatbay-bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2024	6478889	Series B	9090429	6540215	8167196	7313666
Sep 13, 2022	5878377	Series A	1718695	5259308	4820264	Gobi Partners & 1 more
Dec 01, 2021	6245031	Series A	3695383	6531948	Proxima Ventures & 1 more	Aaron Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Greatbay-bio's funding rounds and investors

Greatbay-bio's employee count trend

Greatbay-bio has 34 employees as of Aug 26. Here is Greatbay-bio's employee count trend over the years:

Uncover Greatbay-bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Greatbay-bio include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Greatbay-bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Axol Bioscience 2013, Cambridge (United Kingdom), Series A	Provider of human cells, reagents, and reprogramming services	$13.3M	Calculus Capital, Scottish Enterprise & 13 others	64/100
5th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
6th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
7th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
8th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
9th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 7 others	63/100
174th	Greatbay-bio 2019, Hong Kong (China), Series B	Developer of AI-based cell line development platform	$21.3M	Hillhouse, Vectr Ventures & 14 others	44/100